MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
31 7월 2024 - 7:30PM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of innovative
inhaled therapeutic products and devices for patients with
endocrine and orphan lung diseases, announced today the launch of
an educational website designed to raise awareness of
nontuberculous mycobacterial (NTM) lung disease. LearnAboutNTM.com
is launching today in support of World NTM Awareness Day on August
4.
“NTM lung disease is something many have not heard of before and
that often translates to patients going undiagnosed for years,”
said Dr. Wassim Fares, MSc, FCCP, Senior Vice President,
Therapeutic Area Head, Orphan Lung Diseases of MannKind
Corporation. “MannKind is dedicated to elevating awareness of NTM,
promote early detection and provide a pathway to resources with
this website.”
“It’s inspiring that more companies like MannKind are using
their voice to amplify awareness of NTM and provide an educational
tool for patients living with the disease,” said Amy Leitman, JD,
president of NTM Info & Research, a nonprofit advocacy group
for patients with pulmonary nontuberculous mycobacterial disease.
“Raising awareness helps people know the signs and for patients to
access resources and ultimately timely diagnoses with physicians
for optimum treatment.”
Pulmonary NTM infection is a rare disease with a global health
impact due to its rising prevalence worldwide and association with
shortened life span, high morbidity, and significant impact on
patients’ quality of life. NTM is a group of bacteria naturally
found in our environment, including water and soil, that can lead
to cough, fatigue, a reduction in lung function, and poor quality
of life among other debilitating symptoms. While most people are
exposed to NTM daily, the organisms generally do no harm.
Individuals with underlying conditions such as COPD, asthma, and
bronchiectasis are at increased risk of NTM getting established in
the lungs creating an infection and progressive worsening of lung
function.
There are nearly 200 species of NTM, the most common is MAC
(mycobacterium avium complex), which accounts for about 80% of all
NTM lung disease cases in the United States. While not everyone is
at risk of contracting NTM from MAC, for those who are, it can
cause serious lung damage. NTM lung disease is more common in women
over the age of 65. Estimated 2022 NTM disease prevalence is more
than 100,000 in the U.S. and over 150,000 in Japan. Approximately
15-20% of NTM patients are refractory. The prevalence rate of NTM
is increasing globally – within the U.S. alone claims-based studies
suggest an annual rise of 7.5%.
To learn more about NTM, please visit LearnAboutNTM.com.
About MannKindMannKind Corporation (Nasdaq:
MNKD) focuses on the development and commercialization of
innovative inhaled therapeutic products and devices to address
serious unmet medical needs for those living with endocrine and
orphan lung diseases.
We are committed to using our formulation capabilities and
device engineering prowess to lessen the burden of diseases such as
diabetes, nontuberculous mycobacterial (NTM) lung disease,
pulmonary fibrosis, and pulmonary hypertension. Our signature
technologies – dry-powder formulations and inhalation devices –
offer rapid and convenient delivery of medicines to the deep lung
where they can exert an effect locally or enter the systemic
circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide,
we are on a mission to give people control of their health and the
freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on
LinkedIn, Facebook, X or Instagram.
MANNKIND is a registered trademark of MannKind Corporation.
MannKind Contacts:
Corporate Communications
Christie Iacangelo
(818) 292-3500
Email: media@mnkd.com
Investor Relations
(818) 661-5000
Email: ir@mnkd.com
MannKind (NASDAQ:MNKD)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
MannKind (NASDAQ:MNKD)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024